Notice2022-23379
Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee; Postponement of Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 27, 2022
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA) is postponing the joint meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee scheduled for November 18, 2022. Future meeting dates will be announced in the Federal Register.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 207 (Thursday, October 27, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 207 (Thursday, October 27, 2022)]
[Notices]
[Pages 65070-65071]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-23379]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-1959]
Joint Meeting of the Nonprescription Drugs Advisory Committee and
the Obstetrics, Reproductive and Urologic Drugs Advisory Committee;
Postponement of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; postponement of meeting.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is postponing the joint
meeting of the Nonprescription Drugs Advisory Committee and the
Obstetrics, Reproductive and Urologic Drugs Advisory Committee
scheduled for November 18, 2022. Future meeting dates will be announced
in the Federal Register.
FOR FURTHER INFORMATION CONTACT: Moon Choi, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-2894,
<a href="/cdn-cgi/l/email-protection#fdb3b9bcbebd9b999cd395958ed39a928b"><span class="__cf_email__" data-cfemail="f5bbb1b4b6b5939194db9d9d86db929a83">[email protected]</span></a>, or FDA Advisory Committee Information Line, 1-800-
741-8138 (301-443-0572 in the Washington, DC area). Please call the
Information Line for up-to-date information on this meeting.
SUPPLEMENTARY INFORMATION: The joint meeting of the Nonprescription
Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic
Drugs
[[Page 65071]]
Advisory Committee was originally announced in the Federal Register of
September 13, 2022 (87 FR 56071). The meeting has been postponed to
allow time for FDA to review new information. Future meeting dates will
be announced in the Federal Register.
Dated: October 21, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-23379 Filed 10-26-22; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 27, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.